Imperial Brands offers a range of cigarettes, fine cut and smokeless tobacco, papers, and cigars. Its next generation product (NGP) portfolio includes e-vapour products, oral nicotine and heated tobacco products. The company sells its products under various brands, including Davidoff, Gauloises, JPS, West, L&B, Winston, Parker & Simpson, blu, Pluze, Zone-X, Kool, Horizon, Backwoods, Skruf, Golden Virginia, Rizla and Dutch Masters.
The company also engages in the distribution of tobacco and NGP products for tobacco and NGP product manufacturers, as well as various non-tobacco and NGP products and services. In addition, the company is involved in the management of a golf course; distribution of pharmaceuticals, POS software, and published materials and other products; printing and publishing activities; and provision of long-haul transportation, industrial parcel and express delivery, advertising and support management services. Further, it owns the trademarks and retails its products.
Investors receive a 7.90% dividend. The BofA Securities price objective of $27.70 would be a 52-week high, and the over-the-counter traded American depositary receipts closed on Wednesday at $22.58 apiece.
Novartis
This is among the world’s largest pharmaceutical drug makers by sales and remains a top international pick across Wall Street. Novartis AG (NYSE: NVS) develops, manufactures and markets a range of health care products worldwide.
Novartis operates through three segments: Pharmaceuticals, Alcon and Sandoz. The Pharmaceuticals segment offers patented prescription medicines for oncology, neuroscience, retina, immunology and dermatology, respiratory, cardio-metabolic, established medicines and cell and gene therapies. Key products include Cosentyx (for psoriasis and others), Entresto (heart failure), Lucentis (wet macular degeneration) and Gilenya (multiple sclerosis).
The European Commission recently approved its Tabrecta (capmatinib) drug as a standalone treatment for non-small cell lung cancer patients who had prior treatment with immunotherapy or chemotherapy. The approval is based on the Phase 2 Geometry mono-1 trial, in which treatment with Tabrecta showed positive overall response rates among adult patients, the company said. In the study, the overall response rate was 52% for the group of second-line patients and 44% for those previously treated. The most common adverse events include nausea and fatigue.
Investors receive a 2.65% dividend. The $100 BofA Securities price target compares with a $104.40 consensus target. Wednesday’s closing print for Novartis stock was $81.51.
Sponsored: Find a Qualified Financial Advisor
Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to 3 fiduciary financial advisors in your area in 5 minutes. Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests. If you’re ready to be matched with local advisors that can help you achieve your financial goals, get started now.
